{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:35:06Z","timestamp":1777944906776,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["PY2023006"],"award-info":[{"award-number":["PY2023006"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cranio-Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcms.2025.11.013","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T12:15:56Z","timestamp":1764418556000},"page":"104410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the common ground: Unmasking unique toxicity signatures of cisplatin, docetaxel, and fluorouracil with implications for head and neck cancer treatment"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4011-0282","authenticated-orcid":false,"given":"Simin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaonan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Kreher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Schmalz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcms.2025.11.013_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jcms.2025.11.013_bib2","first-page":"187","article-title":"A phase II study of docetaxel, cisplatin and 5-Fluorouracil (TPF) in patients with locally advanced head and neck carcinomas","volume":"13","author":"Ansari","year":"2011","journal-title":"Iran. Red Crescent Med. J."},{"key":"10.1016\/j.jcms.2025.11.013_bib3","first-page":"559","article-title":"Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck","volume":"26","author":"Baghi","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jcms.2025.11.013_bib4","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1368-7646(02)00047-X","article-title":"Molecular aspects of resistance to antitumor platinum drugs","volume":"5","author":"Brabec","year":"2002","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.jcms.2025.11.013_bib6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon-2023-0513","article-title":"The impact of myelosuppression on quality of life of patients treated with chemotherapy","volume":"20","author":"Crawford","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.681417","article-title":"Chemotherapeutics-induced intestinal mucositis: pathophysiology and potential treatment strategies","volume":"12","author":"Dahlgren","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jcms.2025.11.013_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106939","article-title":"Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies","volume":"203","author":"Elmorsy","year":"2024","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"Suppl. 16","key":"10.1016\/j.jcms.2025.11.013_bib9","first-page":"3","article-title":"Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches","volume":"13","author":"Gale","year":"1985","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jcms.2025.11.013_bib10","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","article-title":"Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial","volume":"28","author":"Ghi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101426","article-title":"Therapeutic approaches for the treatment of head and neck squamous cell carcinoma\u2013An update on clinical trials","volume":"21","author":"Goel","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdy102","article-title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions","volume":"29","author":"Haddad","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib14","first-page":"57","article-title":"Prevention of cisplatin nephrotoxicity","volume":"5","author":"Hayati","year":"2016","journal-title":"J Nephropharmacol"},{"key":"10.1016\/j.jcms.2025.11.013_bib15","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1200\/JCO.21.00637","article-title":"Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort","volume":"39","author":"Hellesnes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0305-7372(03)00097-5","article-title":"Mode of action of docetaxel - a basis for combination with novel anticancer agents","volume":"29","author":"Herbst","year":"2003","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.jcms.2025.11.013_bib17","unstructured":"Kulkarni PS, Das K, Agrawal N, Kala M, Khanduri R, Parikh PM: Pattern of Adverse Drug Reactions to Anticancer Drugs: a Quantitative and Qualitative Analysis."},{"key":"10.1016\/j.jcms.2025.11.013_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jcms.2025.11.013_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial","volume":"12","author":"Lorch","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib20","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins."},{"key":"10.1016\/j.jcms.2025.11.013_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5049\/EBP.2014.12.2.55","article-title":"Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies","volume":"12","author":"Oh","year":"2014","journal-title":"Electrolyte Blood Press."},{"key":"10.1016\/j.jcms.2025.11.013_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.3375","article-title":"The EU\u2010ADR web platform: delivering advanced pharmacovigilance tools","volume":"22","author":"Oliveira","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jcms.2025.11.013_bib23","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/annonc\/mdp573","article-title":"Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study","volume":"21","author":"Paccagnella","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0925-4439(02)00082-0","article-title":"Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism","volume":"1587","author":"Peters","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jcms.2025.11.013_bib25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcms.2025.11.013_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance medicines safety database: publicly accessible data for research and public health protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.jcms.2025.11.013_bib27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s40064-015-0988-5","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety","volume":"4","author":"Qian","year":"2015","journal-title":"SpringerPlus"},{"key":"10.1016\/j.jcms.2025.11.013_bib28","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1\u2013like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.9734\/jpri\/2020\/v32i1130499","article-title":"Safety profile and toxicity amelioration strategies of common adverse effects associated with anticancer medications","volume":"32","author":"Singaraju","year":"2020","journal-title":"J. Pharm. Res. Int."},{"key":"10.1016\/j.jcms.2025.11.013_bib30","first-page":"140","article-title":"Pattern of adverse drug reactions to anticancer drugs: a quantitative and qualitative analysis","volume":"38","author":"Singh","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.jcms.2025.11.013_bib31","doi-asserted-by":"crossref","first-page":"G712","DOI":"10.1152\/ajpgi.00380.2020","article-title":"Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience","volume":"320","author":"Sougiannis","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jcms.2025.11.013_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00066-015-0829-z","article-title":"Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer","volume":"191","author":"Tak\u00e1csi-Nagy","year":"2015","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.jcms.2025.11.013_bib33","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcms.2025.11.013_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2042098616672572","article-title":"Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital","volume":"8","author":"Wahlang","year":"2017","journal-title":"Therapeutic Adv. Drug. Safety."},{"key":"10.1016\/j.jcms.2025.11.013_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Cancer Ther. Rev."}],"container-title":["Journal of Cranio-Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518225003427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518225003427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:02:00Z","timestamp":1773932520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010518225003427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1010518225003427"],"URL":"https:\/\/doi.org\/10.1016\/j.jcms.2025.11.013","relation":{},"ISSN":["1010-5182"],"issn-type":[{"value":"1010-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the common ground: Unmasking unique toxicity signatures of cisplatin, docetaxel, and fluorouracil with implications for head and neck cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Cranio-Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcms.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104410"}}